Scott G Williams

Summary

Affiliation: Peter MacCallum Cancer Centre
Country: Australia

Publications

  1. doi request reprint Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013
    Scott Williams
    Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia Electronic address
    Lancet Oncol 14:e524-34. 2013
  2. pmc A randomised trial of robotic and open prostatectomy in men with localised prostate cancer
    Robert A Gardiner
    University of Queensland Centre for Clinical Research, Royal Brisbane Hospital, Queensland, Australia
    BMC Cancer 12:189. 2012
  3. pmc Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy
    Suki Gill
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Radiat Oncol 6:145. 2011
  4. pmc Expanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapy
    Matthew Beasley
    British Columbia Cancer Agency, Vancouver, Canada
    Radiat Oncol 3:8. 2008
  5. ncbi request reprint Characterization of the behavior of three definitions of prostate-specific antigen-based biochemical failure in relation to detection and follow-up biases: comparison with the American Society for Therapeutic Radiology and Oncology consensus definition
    Scott G Williams
    Peter MacCallum Cancer Centre, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 64:849-55. 2006
  6. doi request reprint Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose
    Scott Williams
    Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 79:724-31. 2011
  7. doi request reprint Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics
    Cécile Proust-Lima
    INSERM, U897, Epidemiology and Biostatistics Research Center, Bordeaux, France
    Int J Radiat Oncol Biol Phys 79:195-201. 2011
  8. ncbi request reprint Radiation therapy of prostate cancer: rationale, pitfalls and the continuing prospect of success forged by medical physics
    S G Williams
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Australas Phys Eng Sci Med 32:119-28. 2009
  9. doi request reprint Does radical treatment have a role in the management of low-risk prostate cancer? The place for brachytherapy and external beam radiotherapy
    Scott G Williams
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, Locked Bag 1 A Beckett St, Melbourne, Vic, 8006, Australia
    World J Urol 26:447-56. 2008
  10. ncbi request reprint Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: statistical significance without predictive performance
    Scott G Williams
    Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 70:1169-75. 2008

Collaborators

Detail Information

Publications23

  1. doi request reprint Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013
    Scott Williams
    Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia Electronic address
    Lancet Oncol 14:e524-34. 2013
    ..This statement of recommendations was formulated by a multidisciplinary panel from Asia-Pacific countries, at a consensus session on prostate cancer that was held as part of the 2013 Asian Oncology Summit in Bangkok, Thailand. ..
  2. pmc A randomised trial of robotic and open prostatectomy in men with localised prostate cancer
    Robert A Gardiner
    University of Queensland Centre for Clinical Research, Royal Brisbane Hospital, Queensland, Australia
    BMC Cancer 12:189. 2012
    ..This paper presents the design of a randomised trial of Robotic and Open Prostatectomy for men newly diagnosed with localised prostate cancer that seeks to answer this question...
  3. pmc Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy
    Suki Gill
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Radiat Oncol 6:145. 2011
    ..We report on toxicity symptoms experienced during radiotherapy treatment, with and without IGRT in prostate cancer patients treated radically...
  4. pmc Expanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapy
    Matthew Beasley
    British Columbia Cancer Agency, Vancouver, Canada
    Radiat Oncol 3:8. 2008
    ....
  5. ncbi request reprint Characterization of the behavior of three definitions of prostate-specific antigen-based biochemical failure in relation to detection and follow-up biases: comparison with the American Society for Therapeutic Radiology and Oncology consensus definition
    Scott G Williams
    Peter MacCallum Cancer Centre, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 64:849-55. 2006
    ..To examine the impact of detection biases on three prostate cancer biochemical failure (bF) definitions in comparison with the existing American Society for Therapeutic Radiology and Oncology Consensus Definition (ACD)...
  6. doi request reprint Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose
    Scott Williams
    Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 79:724-31. 2011
    ..To evaluate the response of clinically localized prostate cancer to various durations of planned androgen deprivation therapy (ADT) and to investigate subgroups predicting response...
  7. doi request reprint Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics
    Cécile Proust-Lima
    INSERM, U897, Epidemiology and Biostatistics Research Center, Bordeaux, France
    Int J Radiat Oncol Biol Phys 79:195-201. 2011
    ..To estimate the α/β ratio of prostate cancer treated with external beam radiation only by use of a model of long-term prostate-specific antigen (PSA) dynamics...
  8. ncbi request reprint Radiation therapy of prostate cancer: rationale, pitfalls and the continuing prospect of success forged by medical physics
    S G Williams
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Australas Phys Eng Sci Med 32:119-28. 2009
    ..Weaknesses in this evidence base are highlighted in relation to areas directly impacted on by the work of medical physics...
  9. doi request reprint Does radical treatment have a role in the management of low-risk prostate cancer? The place for brachytherapy and external beam radiotherapy
    Scott G Williams
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, Locked Bag 1 A Beckett St, Melbourne, Vic, 8006, Australia
    World J Urol 26:447-56. 2008
    ..This article aims to review data regarding LRPCa and radiotherapy outcomes, and highlight the potential challenges to improve this data in a planned manner...
  10. ncbi request reprint Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: statistical significance without predictive performance
    Scott G Williams
    Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 70:1169-75. 2008
    ..To define and incorporate the impact of the percentage of positive biopsy cores (PPC) into a predictive model of prostate cancer radiotherapy biochemical outcome...
  11. ncbi request reprint Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer
    Scott G Williams
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 68:24-33. 2007
    ..To examine the effect of fraction size and total dose of radiation on recurrence of localized prostate cancer...
  12. ncbi request reprint An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk
    Scott G Williams
    Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 65:351-7. 2006
    ..To evaluate the impact of an alternative biochemical failure (bF) definition on the performance of existing plus de novo prognostic models...
  13. ncbi request reprint A multicenter study demonstrating discordant results from electronic prostate-specific antigen biochemical failure calculation systems
    Scott G Williams
    Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 65:1494-500. 2006
    ..To evaluate the interobserver variation of four electronic biochemical failure (bF) calculators using three bF definitions...
  14. doi request reprint High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial
    Maroie Barkati
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia
    Int J Radiat Oncol Biol Phys 82:1889-96. 2012
    ..High-dose-rate (HDR) brachytherapy as a monotherapy is appealing, but its use is still investigational. A Phase II trial was undertaken to explore the value of such treatment in low-to-intermediate risk prostate cancer...
  15. ncbi request reprint What defines intermediate-risk prostate cancer? Variability in published prognostic models
    Scott G Williams
    William Buckland Radiotherapy Centre, The Alfred Hospital, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 58:11-8. 2004
    ..To assess the efficacy of a variety of prognostic models in the definition of intermediate-risk prostate cancer and to compare them to our own empiric model...
  16. ncbi request reprint Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer
    Scott G Williams
    William Buckland Radiotherapy Centre and Monash University, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 60:1082-7. 2004
    ..To assess the impact of pretreatment prognostic factors plus subsequent biochemical failure on overall survival after radiotherapy for prostate cancer...
  17. ncbi request reprint Ambiguities within the ASTRO consensus definition of biochemical failure: never assume all is equal
    Scott G Williams
    William Buckland Radiotherapy Centre, The Alfred Hospital, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 58:1083-92. 2004
    ..To quantitate the impact of a number of variables within the American Society of Therapeutic Radiology and Oncology consensus definition (ACD) of biochemical failure (bF) for prostate cancer...
  18. ncbi request reprint Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy
    Scott G Williams
    Department of Radiation Oncology, William Buckland Radiotherapy Centre, The Alfred Hospital, Commercial Road, Melbourne, VIC 3004, Australia
    Radiother Oncol 73:33-8. 2004
    ..To assess factors related to the risk of acute urinary retention and other morbidity indices in patients undergoing transperineal seed implantation of the prostate...
  19. doi request reprint Urethral stricture following high dose rate brachytherapy for prostate cancer
    Lisa Sullivan
    Division of Radiation Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Australia
    Radiother Oncol 91:232-6. 2009
    ..To evaluate the incidence, timing, nature and outcome of urethral strictures following high dose rate brachytherapy (HDRB) for prostate carcinoma...
  20. ncbi request reprint Soy and soy isoflavones in prostate cancer: a systematic review and meta-analysis of randomized controlled trials
    M Diana van Die
    Department of General Practice, University of Melbourne, Parkville, Vic
    BJU Int 113:E119-30. 2014
    ..To evaluate the evidence from randomized controlled trials (RCTs) on the efficacy and safety of soy/isoflavones in men with prostate cancer (PCa) or with a clinically identified risk of PCa...
  21. doi request reprint In patients experiencing biochemical failure after radiotherapy, pretreatment risk group and PSA velocity predict differences in overall survival and biochemical failure-free interval
    Daniel E Soto
    Department of Radiation Oncology, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    Int J Radiat Oncol Biol Phys 71:1295-301. 2008
    ..To characterize the demographics and survival outcomes of localized prostate cancer patients who developed biochemical failure (BF) according to a prostate-specific antigen (PSA) nadir plus 2 ng/mL...
  22. ncbi request reprint A prospective dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer: Evidence of hypofractionation efficacy?
    Johann I Tang
    Department of Radiation Oncology, The Cancer Institute, National University Hospital, Singapore
    Brachytherapy 5:256-61. 2006
    ..The study aimed to evaluate mature outcomes of a Phase I/II high-dose-rate brachytherapy (HDRB) boost protocol...
  23. ncbi request reprint In regards to Thames et al.: increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. (Int J Radiat Oncol Biol Phys 2006;65:975-981)
    Tom Pickles
    Int J Radiat Oncol Biol Phys 67:318-9; author reply 319. 2007